CN100491399C - Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof - Google Patents

Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof Download PDF

Info

Publication number
CN100491399C
CN100491399C CNB2005101191435A CN200510119143A CN100491399C CN 100491399 C CN100491399 C CN 100491399C CN B2005101191435 A CNB2005101191435 A CN B2005101191435A CN 200510119143 A CN200510119143 A CN 200510119143A CN 100491399 C CN100491399 C CN 100491399C
Authority
CN
China
Prior art keywords
protein
gene
cancer
filobactivirus
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005101191435A
Other languages
Chinese (zh)
Other versions
CN1803846A (en
Inventor
王丽
华攀玉
高瑞娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northeast Normal University
Original Assignee
Northeast Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Normal University filed Critical Northeast Normal University
Priority to CNB2005101191435A priority Critical patent/CN100491399C/en
Publication of CN1803846A publication Critical patent/CN1803846A/en
Application granted granted Critical
Publication of CN100491399C publication Critical patent/CN100491399C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention belongs to the DNA recombination field in bioengineering. Wherein, with the recombination technique, inserting the gene fragment of B cell epitope composed by 37-46 peptide fragments on N-end of P53 protein into the carrier integrated with main coat protein gene of filamentous phage to form the new recombinant plasmid; in host, secreting the epitope gene product out of the cell to assemble in coat protein and form heterozygous protein that can be used as a antigen to detect antibody in clinical tumor patient serum (such as, gastric cancer, liver cancer, breast cancer and lung cancer).

Description

The hybrid protein and the application thereof of proteic epi-position of p53 and filobactivirus gene 8 protein
Technical field
The invention belongs to the DNA recombinant technology field in the biotechnology.
Background technology
Tumour is the second in the world number that is only second to cardiovascular disorder " killer " disease.By to the end of the year 1999, global tumour patient sum has exceeded 4,000 ten thousand people.China has 1,300,000 people to die from tumour every year.At present, also lack the medicine that to diagnose effectively, to prevent and to treat the carrying out of tumour.
P53 is a kind of cancer suppressor gene, and its albumen is to keeping the normal cell fission and the important regulatory role of grow, but in case undergo mutation, the prolongation of mutain transformation period loses cancer suppressing action, accumulates in cell then stimulating immune system generation corresponding antibodies.The gene fragment of the B cell epitope that N end 20-25 peptide section, 37-46 peptide section constitute is inserted in the carrier that is integrated with the main coat protein gene of filobactivirus, is built into new recombinant vectors.This recombinant vectors is changed over to the host bacterium, and in the intestinal bacteria, under the condition that helper phage exists, tumour epitope gene product is secreted into the extracellular, and is assembled in the bacteriophage coat protein, forms the hybrid protein with corresponding epi-position.(Rui-juan Gao, Hui-zheng Bao, QiongYang, Qi Cong, Jin-na Song, Li Wang*.The presence of serum anti-p53 antibodiesfrom patients with invasive ductal carcinoma of breast:correlation to otherclinical and biological parameters.Breast Cancer Research and Treatment.2005; 93 (2): 111-115; Wang Li. the displaying of polypeptide on filamentous phage coat protein. Northeast China Normal University's journal, 1998 the 1st phases: 46-48).
The advantage of utilizing phage display allogenic polypeptide technology is to have realized the external conversion of genotype and phenotype effectively, make the investigator can on gene molecule clone's basis, realize the external control of protein conformation fully effectively, have good biological in external acquisition and learn active expression product.This novel genetic engineering technique has aspect the preparation biological products: easy, quick, sensitive, low cost and other advantages (Wang Li*.Foreign peptides displayed on the major coatprotein of filamentous bacteriophage.Chinese Science Bulletin, 1998.Vol.43 No.12:1242-1246).
Summary of the invention
The objective of the invention is to establish a kind of biological products that the preparation clinical tumor detects that can be used in.
Hybrid protein of the present invention is the filobactivirus gene 8 heterozygosis coat protein that contain the epi-position of human p53N end 37-46 peptide section formation.
The nucleotide sequence of P53-37-46 hybrid protein gene:
atg?aaa?aag?tct?tta?gtc?ctc?aaa?gcc?tcc?gta?gcc?gtt?gct?acc?ctc 48
gtt?ccg?atg?ctg?tct?ttc?gcc?gcg?gag?ggt?tct?caa?gct?atg?gat?gat 96
tta?atg?tta?tct?cca?tcg?aac?gat?cct?gca?aaa?gcg?gcc?ttt?gac?tcc 144
ctg?caa?gcc?tca?gcg?acc?gaa?tat?atc?ggt?tat?gcg?tgg?gcg?atg?gtt 192
gtt?gtc?att?gtc?ggc?gca?act?atc?ggt?atc?aag?ctg?ttt?aag?aaa?ttc 240
acc?tcg?aaa?gca?agc 255
The aminoacid sequence of P53-37-46 hybrid protein is:
Met?Lys?Lys?Ser?Leu?Val?Leu?Lys?Ala?Ser?Val?Ala?ValAla?Thr
1 5 10 15
Leu?Val?Pro?Met?Leu?Ser?Phe?Ala?Ala?Glu?Gly?Ser?Gln?Ala?Met
20 25 30
Asp?Asp?Leu?Met?Leu?Ser?Pro?Ser?Asn?Asp?Pro?Ala?Lys?Ala?Ala
35 40 45
Phe?Asp?Ser?Leu?Gln?Ala?Ser?Ala?Thr?Glu?Tyr?Ile?Gly?Tyr?Ala
50 55 60
Trp?Ala?Met?Val?Val?Val?Ile?Val?Gly?Ala?Thr?Ile?Gly?Ile?Lys
65 70 75
Leu?Phe?Lys?Lys?Phe?Thr?Ser?Lys?Ala?Ser
80 85
The preparation of hybrid protein may further comprise the steps:
The first step, construction of expression vector and recombinant vectors.
Handle the pfd88 plasmid with SacII and two kinds of restriction enzymes of BstB I, the oligonucleotide fragment with synthetic is inserted into the plasmid vector of handling through enzyme then, obtains recombinant vectors pfd8p53-37.
Second goes on foot, and synthesizes the gene order of p53 albumen n end 37-46 peptide segment table position, and adds restriction enzyme site at the sequence two ends.Dna synthesizer with commercial company carries out synthetic.The sequence of epitope gene is: (be 5 '-3 ' direction)
Positive-sense strand:
GGAGGGTTCTCAAGCTATGGATGATTTAATGTTATCTCCAT
Antisense strand:
CGATGGAGATAACATTAAATCATCCATAGCTTGAGAACCCTCCGC。
In the 3rd step, change recombinant vectors over to host cell.Host cell is the large intestine bacterial strain TG1 bacterial strain that has F-factor.The transformant that obtains is new engineering strain pfd8p53-37.
The 4th step, the preparation hybrid protein.The culturing engineering bacterial strain, steps such as process is centrifugal, precipitation can obtain the hybrid protein of this invention.
Immunodetection:
The antibody that hybrid protein can be used as among a kind of antigen and the kinds of tumors patients serum produces immunne response: the hybrid protein with the present invention's preparation is an antigen, adopt immunologic detection method (as ELISA), can detect clinical tumor (such as, cancer of the stomach, colon knurl, liver cancer, mammary cancer and lung cancer etc.) associated antibodies among the patients serum.Illustrate that this hybrid protein can be used for preparing the detection of drugs of clinical tumor.
Embodiment
1. epitope gene is synthetic:
Utilize the dna synthesizer of commercial biotech firm to carry out the epitope gene fragment
GGAGGGTTCTCAAGCTATGGATGATTTAATGTTATCTCCAT,
Synthesizing CGATGGAAGTAACATTAAATCATCCATAGCTTGAGAACCCTCCGC).
2. the structure of recombinant vectors
1) gets pfd88 plasmid 5 μ g, add the SacII enzyme of 1-2 μ L, add damping fluid and sterilized water then to cumulative volume 200 μ l.37 ℃ are incubated 24 hours.After enzyme is cut, with ordinary method extracting plasmid DNA.After the extracting,, and be dissolved in the 50 μ L TE liquid with amine acetate and the long-pending ethanol sedimentation DNA of diploid.
2) handle first kind of plasmid DNA that enzyme is cut with second kind of restriction enzyme BstBI, method is the same.
3) behind the double digestion, carry out agarose gel electrophoresis, measure carrier concn.
4) carrier mixes by mole concentration 1:3 with the exogenous dna fragment of synthetic.10 μ L mixed solutions add 0.5 μ LT 4Dna ligase and 1 μ L damping fluid.Under 15-20 ℃ of condition, overnight incubation obtains recombinant vectors (pfd8p53-37).
3. preparation competent cell
The TG1 cell cultures on the LB substratum, was cultivated 16-20 hour for 37 ℃.Select single colony inoculation in 2ml LB liquid culture medium, 37 ℃ of overnight incubation.Nutrient solution changes in the fresh LB nutrient solution of 100ml, cultivates 5 hours for 37 ℃.Centrifugal 15 minutes of 5000rpm.0.1mol/L CaCl with the 8ml precooling 2Suspend and precipitate, obtain competent cell.
4. recombinant vectors transformed host cell
Get the recombinant vectors dna solution 1.25 μ L that concentration is about 150 μ g/mL; The competent cell that adds 100 μ l placed trash ice 15 minutes; Add 600 μ l LB nutrient solutions, place 37 ℃ of constant temperatures to cultivate 1 hour; Centrifugal 5 minutes of 10000rpm; Abandon supernatant, remainder is applied to the LB media surface that contains penbritin, overnight incubation in 37 ℃ of thermostat containers.Be selected in single bacterium colony of cultivating planar growth, carry out enlarged culturing and cryopreservation (70 ℃).
5. the preparation of hybrid protein
It is streak culture on the LB flat board to get frozen transformant, spends the night; The menu colony inoculation in the 3mlLB nutrient solution that contains penbritin, 37 ℃ of overnight incubation; Change nutrient solution in 80-100ml LB nutrient solution continuation cultivation, and add IPTG (final concentration is 0.5-1mM/mL), cultivated 30 minutes for 37 ℃; Centrifugal (10 000rpm) 10 minutes; Precipitation suspends again with nutrient solution, cultivates 2-4 hour for 37 ℃; Centrifugal (8000rmp) 20 minutes abandons supernatant, suspends with TE liquid and precipitates; Centrifugal (5000rmp) 20 minutes gets supernatant, and adds 20% polyoxyethylene glycol and 2.5mol/L sodium-chlor.Placed 4-5 hour centrifugal (8000rmp) 10 minutes in the cold environment; Abandon supernatant, suspend with TE liquid and precipitate, obtain the filobactivirus heterozygosis coat protein that has allogenic polypeptide to show.
6. the detection of Zhi Bei hybrid protein
1) adopt SDS-polyacrylamide gel electrophoresis to carry out proteic purity detecting
The testing protein sample was handled in boiling water 3-5 minute.Carry out electrophoresis according to a conventional method.Behind the electrophoresis, offset plate is dyeed with silver nitrate method staining.If hybrid protein is expressed successfully, two bands appear on the offset plate.The top band is the hybrid protein band, and the below is a wild-type filamentous phage coat protein band.Because silver nitrate method staining is relatively sensitiveer,, illustrate that the albumen of preparation has reached pure standard as there not being other assorted taking out of now on the offset plate.
2) adopting ultraviolet spectrophotometry to be prepared proteic concentration detects
Get the sample of 5-10 μ L, dilute 100 times after, be determined at the light absorption value of 270 nanometers.With light absorption value divided by 3.84 concentration (μ g/ μ L) that just obtain protein solution.
7. immunodetection experiment
Take the ELISA method, as envelope antigen, person's to be checked serum is detected with het.Antigenic bag is 60 μ g/mL by concentration, an anti-patients serum for 200 times of dilutions, and two anti-ly are the goat anti-human igg.Dyeing process adopts the TMB method.Detecting wavelength is 450/620.The result that 367 tumour patient serum are detected shows: colorectal carcinoma 28.6% (8/28), the esophageal carcinoma 27.3% (6/22), cancer of the stomach 26.9% (7/26), lung cancer 23.5% (23/98), nasopharyngeal carcinoma 23.1% (3/13), mammary cancer 1 8.8% (27/144), ovarian cancer 18.2% (2/11), brain tumor 16.7% (2/12), liver cancer 15.4% (2/13).The specific degree 94.2% that detects, sensitivity is 21.8%.
SEQUENCE?LISTING
<110〉Northeast Normal University
<120〉hybrid protein and the application thereof of proteic epi-position of p53 (SQAMDDLMLS) and filobactivirus gene 8 protein
<130>none
<140>---------
<141>2005-10-23
<160>2
<170>PatentIn?version?3.1
<210>1
<211>255
<212>DNA
<213>Artificial?sequence
<220>
<223〉recombination sequence of p53 albumen epi-position (SQAMDDLMLS) gene fragment and filobactivirus gene VIII
<220>
<221>CDS
<222>(1)..(255)
<223>
<220>
<221>misc_recomb
<222>(79)..(108)
<223>
<300>
<302〉hybrid protein and the application thereof of proteic epi-position of p53 (SQAMDDLMLS) and filobactivirus gene 8 protein
<308>none
<309>2007-04-25
<310>none
<311>2005-10-25
<312>2007-04-25
<313>(1)..(255)
<400>1
<210>2
<211>85
<212>PRT
<213>Artificial?sequence
<220>
<223〉recombination sequence of p53 albumen epi-position (SQAMDDLMLS) gene fragment and filobactivirus gene VIII
<400>2
Figure C200510119143D00101

Claims (2)

1, the hybrid protein of proteic epi-position SQAMDDLMLS of a kind of P53 and filobactivirus gene 8 protein, the aminoacid sequence that it is characterized in that this hybrid protein are shown in the sequence 2 in the sequence table.
2, be used to prepare the purposes of the clinical detection medicine that detects tumour by the described hybrid protein of claim 1.
CNB2005101191435A 2005-12-27 2005-12-27 Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof Expired - Fee Related CN100491399C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005101191435A CN100491399C (en) 2005-12-27 2005-12-27 Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005101191435A CN100491399C (en) 2005-12-27 2005-12-27 Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof

Publications (2)

Publication Number Publication Date
CN1803846A CN1803846A (en) 2006-07-19
CN100491399C true CN100491399C (en) 2009-05-27

Family

ID=36866014

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005101191435A Expired - Fee Related CN100491399C (en) 2005-12-27 2005-12-27 Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof

Country Status (1)

Country Link
CN (1) CN100491399C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101684145B (en) * 2008-09-23 2012-10-17 北京市结核病胸部肿瘤研究所 Antigen peptide identified by p53 antoantibody, kit and application thereof in preparing tumor detection kit
CN111100209A (en) * 2020-01-17 2020-05-05 新乡学院 Recombinant protein G3P20-31 and preparation method and application thereof
CN111138554A (en) * 2020-01-17 2020-05-12 新乡学院 Recombinant protein G3P1-12 and preparation method and application thereof
CN113403286B (en) * 2021-06-24 2024-01-16 新乡学院 Targeting three-display phage and preparation method and application thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
p53/p21融合基因的克隆及其对Tca8113细胞生长的影响. 余优成,顾章愉,陈万涛,张志愿.中华口腔医学杂志,第38卷第2期. 2003
p53/p21融合基因的克隆及其对Tca8113细胞生长的影响. 余优成,顾章愉,陈万涛,张志愿.中华口腔医学杂志,第38卷第2期. 2003 *
Prophylactic vaccination with phage-displayed epitope of C.albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Qiong Yang等.Vaccine,Vol.23 No.31. 2005
Prophylactic vaccination with phage-displayed epitope of C.albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Qiong Yang等.Vaccine,Vol.23 No.31. 2005 *
Tat-p53融合蛋白的表达、纯化及其转导活性. 丁劲,刘军,黄豫晓,李英辉,陈俊,赵亚,薛采芳.细胞与分子免疫学杂志,第21卷第5期. 2005
Tat-p53融合蛋白的表达、纯化及其转导活性. 丁劲,刘军,黄豫晓,李英辉,陈俊,赵亚,薛采芳.细胞与分子免疫学杂志,第21卷第5期. 2005 *
不同的引导肽对丝状噬菌体基因8蛋白展示外源多肽的影响. 王丽,华攀玉,高瑞娟,杨琼,宋金娜.高等学校化学学报,第26卷第6期. 2005
抗人CD3单链抗体/p53四聚功能域融合基因的构建及表达. 武国军,白玉杰,王栋,于磊,王智,王禾,药立波.细胞与分子免疫学杂志,第20卷第5期. 2004

Also Published As

Publication number Publication date
CN1803846A (en) 2006-07-19

Similar Documents

Publication Publication Date Title
CN102121023B (en) Mutant human plasminogen kringle5, preparation method and application thereof
CN109336976A (en) The nano antibody of anti-human EGFR and its application
ES2252946T3 (en) BASB029 POLYUCLEOTIDES AND POLYPEPTIDES DERIVED FROM NEISSERIA MENINGITIS.
CN102746382A (en) B-cell epitope peptide of heart fatty acid binding protein (H-FABP), antibody and applications thereof
CN110317278A (en) The fusion protein and its encoding gene of SVV and FMDV, expression vector, cell line, engineering bacteria and vaccine and application
CN105106945B (en) A kind of helicobacter pylori tetravalence virulence factor polyepitope vaccines and preparation method thereof
CN100491399C (en) Hybrid protein of p53 protein epitope and filobactivirus gene 8 protein and application thereof
CN101302526A (en) Recombinant soluble streptococcus hemolyticus haemolysin O gene, recombinant protein and preparation thereof
CN103710367B (en) A kind of recombined human kallikrein 1 and encoding gene thereof and preparation method
CN105542010A (en) Lipoprotein-associated phospholipase A2 monoclonal antibodies, antibody pairs, preparation method and application
CN107236046A (en) A kind of recombinant human endostatin fusion protein and its preparation method and application
CN103360497A (en) Novel antitumor fusion protein vaccine, and preparation method and application thereof
CN106905434A (en) A kind of recombination fusion protein comprising hoof bat hepatitis B core protein and its preparation method and application
CN105505943B (en) A kind of 3 standard items of pregnancy glycoprotin, preparation method and the recombinant bacterium being used to prepare
WO2020024594A1 (en) Preparation method and application of recombinant mutant collagenase
CN105296515B (en) A kind of fusion protein and its preparation method and application of interferon A 2b and collagen binding domain
CN106676121A (en) Method for simply and conveniently preparing active human KGF-2D31
CN103497926B (en) The recombinant BCG viable bacteria bacterial strain of expression-secretion mankind p53 albumen, live bacterial vaccines and construction process thereof and application
CN108314735B (en) Monoclonal antibody for resisting rat babesia and application thereof
CN101240284B (en) Recombination staphylokinase and highly effective secretion expression method thereof
CN103642812B (en) A kind of bolti antiapoptotic factors FasL gene and application thereof
CN109134654A (en) A kind of single-chain antibody of targeting EGFR dimerization interface and its application
CN109576229A (en) A kind of monoclonal antibody hybridoma cell strain and its application for secreting anti-AGR2
CN109652414A (en) Construct the hog cholera Attenuated Salmonella recombinant bacterial strain of one plant of expression haemophilus parasuis Omp26 gene
CN103387605A (en) RTN4B polypeptide and monoclonal antibody thereof, hybridoma cell strain generating monoclonal antibody, and preparation and application of RTN4B polypeptide, monoclonal antibody and hybridoma cell strain

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090527

Termination date: 20181227

CF01 Termination of patent right due to non-payment of annual fee